Healthcare
Wednesday, September 21, 2016
BRIEF-Bluebird Bio's LentiGlobin investigational gene therapy accepted into Europen Medicines Agency's PRIME program
* LentiGlobin(TM) investigational gene therapy for
transfusion-dependent beta-thalassemia accepted into European
Medicines Agency's PRIME program
Source text for Eikon:
Further company coverage:
Read more
No comments:
Post a Comment
Newer Post
Older Post
Home
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment